Effect of c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinase (p38 MAPK) in morphine-induced tau protein hyperphosphorylation

Behavioural Brain Research

Volumn 237, Issue 1, 2013, Pages 249-255

  Cao, Minghui ^a,b   Liu, Funing ^a   Ji, Fengtao ^a   Liang, Jianjun ^a   Liu, Ling ^a   Wu, Qiang ^a   Wang, Tinghuai ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

JNK; Morphine; Opioids; P38 MAPK; Tau Phosphorylation

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHINE SULFATE; NALOXONE; OPIATE RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REPRESSION; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; ANTHRACENES; CELLS, CULTURED; CEREBRAL CORTEX; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 8; MORPHINE; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS; TIME FACTORS;

EID: 84867616201     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.09.040     Document Type: Article

References (52)

1. Leshner A.I. Addiction is a brain disease, and it matters. Science 1997, 278:45-47.
2. Rapeli P., Kivisaari R., Autti T., Kähkönen S., Puuskari V., Jokela O., et al. Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls. BMC Psychiatry 2006, 6:9.
3. Olesen A.E., Staahl C., Arendt-Nielsen L., Drewes A.M. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. British Journal of Clinical Pharmacology 2010, 70:189-200.
4. Rauf K., Subhan F., Abbas M., Badshah A., Ullah I., Ullah S. Effect of Bacopasides on acquisition and expression of morphine tolerance. International Journal of Phytotherapy and Phytopharmacology 2011, 18:836-842.
5. Ma M.X., Chen Y.M., He J., Zeng T., Wang J.H. Effects of morphine and its withdrawal on Y-maze spatial recognition memory in mice. Neuroscience 2007, 147:1059-1065.
6. Wu Y., Chen R., Zhao X., Li A., Li G., Zhou J. JWA regulates chronic morphine dependence via the delta opioid receptor. Biochemical and Biophysical Research Communications 2011, 409:520-525.
7. Ramage S.N., Anthony I.C., Carnie F.W., Busuttil A., Robertson R., Bell J.E. Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. Neuropathology and Applied Neurobiology 2005, 31:439-448.
8. Drewes G., Lichtenberg-Kraag B., Doring F., Mandelkow E.M., Biernat J., Goris J., et al. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO Journal 1992, 11:2131-2138.
9. Lee H.G., Perry G., Moreira P.I., Garrett M.R., Liu Q., Zhu X., et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector. Trends in Molecular Medicine 2005, 11:164-169.
10. Kaneto H., Nakatani Y., Kawamori D., Miyatsuka T., Matsuoka T., Matsuhisa M., et al. Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. The International Journal of Biochemistry & Cell Biology 2005, 37:1595-1608.
11. Abdelli S., Abderrahmani A., Hering B.J., Beckmann J.S., Bonny C. The c-Jun N-terminal kinase JNK participates in cytokine- and isolation stress-induced rat pancreatic islet apoptosis. Diabetologia 2007, 50:1660-1669.
12. Weston C.R., Davis R.J. The JNK signal transduction pathway. Current Opinion in Cell Biology 2007, 19:142-149.
13. Nateri A.S., Spencer-Dene B., Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 2005, 437:281-285.
14. Tuncman G., Hirosumi J., Solinas G., Chang L., Karin M., Hotamisligil G.S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10741-10746.
15. Wilhelm M., Xu Z., Kukekov N.V., Gire S., Greene L.A. Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model. Journal of Biological Chemistry 2007, 282:1288-1295.
16. Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R., et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. Journal of Neuroscience 2001, 21:7551-7560.
17. Reynolds C.H., Utton M.A., Gibb G.M., Yates A., Anderton B.H. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. Journal of Neurochemistry 1997, 68:1736-1744.
18. Yoshida H., Hastie C.J., McLauchlan H., Cohen P., Goedert M. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). Journal of Neurochemistry 2004, 90:352-358.
19. Schechter R., Beju D., Miller K.E. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochemical and Biophysical Research Communications 2005, 334:979-986.
20. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. Journal of Neuroscience 2003, 23:1605-1611.
21. Mendonsa G., Dobrowolska J., Lin A., Vijairania P., Jong Y.J., Baenziger N.L. Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblasts. PLoS ONE 2009, 4:e4655.
22. Macey T.A., Lowe J.D., Chavkin C. Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons. Journal of Biological Chemistry 2006, 281:34515-34524.
23. Cui Y., Chen Y., Zhi J.L., Guo R.X., Feng J.Q., Chen P.X. Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Research 2006, 1069:235-243.
24. Park D.S., Morris E.J., Padmanabhan J., Shelanski M.L., Geller H.M., Greene L.A. Cyclin-dependent kinases participate in death of neurons evoked by DNA-damaging agents. Journal of Cell Biology 1998, 143:457-467.
25. Lahti A., Sareila O., Kankaanranta H., Moilanen E. Inhibition of p38 mitogen-activated protein kinase enhances c-Jun N-terminal kinase activity: implication in inducible nitric oxide synthase expression. BMC Pharmacology 2006, 6:5.
26. Heinrichsdorff J., Luedde T., Perdiguero E., Nebreda A.R., Pasparakis M. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Reports 2008, 9:1048-1054.
27. Sundaramurthy P., Gakkhar S., Sowdhamini R. Computational prediction and analysis of impact of the cross-talks between JNK and P38 kinase cascades. Bioinformation 2009, 3:250-254.
28. Ma W., Zheng W.H., Powell K., Jhamandas K., Quirion R. Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study. European Journal of Neuroscience 2001, 14:1091-1104.
29. Avila J., Lucas J.J., Perez M., Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiological Reviews 2004, 84:361-384.
30. Charlesworth G., Gandhi S., Bras J.M., Barker R.A., Burn D.J., Chinnery P.F., et al. Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiology of Aging 2012, 33:837-838.
31. Mi K., Johnson G.V. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Current Alzheimer Research 2006, (5):440-463.
32. Duka T., Duka V., Joyce J.N., Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. Federation of American Societies for Experimental Biology Journal 2009, 9:2820-2830.
33. Gong C.X., Grundke-Iqbal I., Iqbal K. Targeting tau protein in Alzheimer's disease. Drugs Aging 2010, (5):351-365.
34. Pu L., Bao G.B., Xu N.J., Ma L., Pei G. Hippocampal long-term potentiation is reduced by chronic opiate treatment and can be restored by re-exposure to opiates. Journal of Neuroscience 2002, 22:1914-1921.
35. Bao G., Kang L., Li H., Li Y., Pu L., Xia P., et al. Morphine and heroin differentially modulate in vivo hippocampal LTP in opiate-dependent rat. Neuropsychopharmacology 2007, 32:1738-1749.
36. Lu G., Zhou Q.X., Kang S., Li Q.L., Zhao L.C., Chen J.D., et al. Chronic morphine treatment impaired hippocampal long-term potentiation and spatial memory via accumulation of extracellular adenosine acting on adenosine A1 receptors. Journal of Neuroscience 2010, 30:5058-5070.
37. Hernandez P., Lee G., Sjoberg M., Maccioni R.B. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts. Journal of Alzheimer's Disease 2009, 16:149-156.
38. Rankin C.A., Sun Q., Gamblin T.C. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Molecular Neurodegeneration 2007, 2:12.
39. Yoshimura Y, Ichinose T, Yamauchi T., Le W. Phosphorylation of tau protein to sites found in Alzheimer's disease brain is catalyzed by Ca2+/calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry. Neuroscience Letters 2003, 3:158.
40. Kelly A., Vereker E., Nolan Y., Brady M., Barry C., Loscher C.E., et al. Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. Journal of Biological Chemistry 2003, 278:19453-19462.
41. Karunakaran S., Saeed U., Mishra M., Valli R.K., Joshi S.D., Meka D.P., et al. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Journal of Neuroscience 2008, 28:12500-12509.
42. Kuan C.Y., Burke R.E. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Current Drug Targets: CNS and Neurological Disorders 2005, 4:63-67.
43. Peng J., Andersen J.K. The role of c-Jun N-terminal kinase (JNK) in Parkinson's disease. IUBMB Life 2003, 55:267-271.
44. Clerk A., Sugden P.H. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Letters 1998, 426:93-96.
45. Harada J., Sugimoto M. An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. Japanese Journal of Pharmacology 1999, 79:369-378.
46. Henklova P., Vrzal R., Papouskova B., Bednar P., Jancova P., Anzenbacherova E., et al. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. European Journal of Pharmacology 2008, 593:16-23.
47. Reynolds C.H., Betts J.C., Blackstock W.P., Nebreda A.R., Anderton B.H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. Journal of Neurochemistry 2000, 74:1587-1595.
48. Jaquet P.E., Ferrer-Alcon M., Ventayol P., Guimon J., Garcia-Sevilla J.A. Acute and chronic effects of morphine and naloxone on the phosphorylation of neurofilament-H proteins in the rat brain. Neuroscience Letters 2001, 304:37-40.
49. Perucho J., Rubio I., Casarejos M.J., Gomez A., Rodriguez-Navarro J.A., Solano R.M., et al. Anesthesia with isoflurane increases amyloid pathology in mice models of Alzheimer's disease. Journal of Alzheimer's Disease 2010, 19:1245-1257.
50. Planel E., Richter K.E., Nolan C.E., Finley J.E., Liu L., Wen Y., et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. Journal of Neuroscience 2007, 27:3090-3097.
51. Semple T.J., Upton R.N., Macintyre P.E., Runciman W.B., Mather L.E. Morphine blood concentrations in elderly postoperative patients following administration via an indwelling subcutaneous cannula. Anaesthesia 1997, 52:318-323.
52. Aragon C.L., Read M.R., Gaynor J.S., Barnhart M.D., Wilson D., Papich M.G. Pharmacokinetics of an immediate and extended release oral morphine formulation utilizing the spheroidal oral drug absorption system in dogs. Journal of Veterinary Pharmacology and Therapeutics 2009, 32:129-136.